TVARDI THERAPEUTICS, INC. Lease, Cost
TVARDI THERAPEUTICS, INC. (TVRD) reported Lease, Cost of $45.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. lease, cost for the quarter ending 2026-06-30 was $45.00K, a 7.14% increase year-over-year.
- TVARDI THERAPEUTICS, INC. lease, cost for the quarter ending 2026-03-31 was $46.00K, a 0.00% change year-over-year.
- TVARDI THERAPEUTICS, INC. lease, cost for the quarter ending 2025-12-31 was $46.00K, a 8.00% decline year-over-year.
- TVARDI THERAPEUTICS, INC. lease, cost for the quarter ending 2025-09-30 was $45.00K, a 4.65% increase year-over-year.
- TVARDI THERAPEUTICS, INC. lease, cost for fiscal 2025 was $179.00K, a 1.70% increase from fiscal 2024.
- TVARDI THERAPEUTICS, INC. lease, cost for fiscal 2024 was $176.00K.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.00K 10-Q · filed 2026-08-14 | $91.00K 10-Q · filed 2026-08-14 | $137.00K derived: sum of 3 quarters · filed 2026-08-14 | $182.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $46.00K 10-Q · filed 2026-05-08 | $92.00K derived: sum of 2 quarters · filed 2026-05-08 | $137.00K derived: sum of 3 quarters · filed 2026-05-08 | $179.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $91.00K derived: sum of 2 quarters · filed 2026-03-31 | $133.00K derived: sum of 3 quarters · filed 2026-08-14 | $179.00K 10-K · filed 2026-03-31 |
| 2025-09-30 | $45.00K 10-Q · filed 2025-11-13 | $87.00K derived: sum of 2 quarters · filed 2026-08-14 | $133.00K 10-Q · filed 2025-11-13 | $183.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $42.00K 10-Q · filed 2026-08-14 | $88.00K 10-Q · filed 2026-08-14 | $138.00K derived: sum of 3 quarters · filed 2026-08-14 | $181.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $46.00K 10-Q · filed 2026-05-08 | $96.00K derived: sum of 2 quarters · filed 2026-05-08 | $139.00K derived: sum of 3 quarters · filed 2026-05-08 | $179.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $93.00K derived: sum of 2 quarters · filed 2026-03-31 | $133.00K derived: sum of 3 quarters · filed 2026-03-31 | $176.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $43.00K 10-Q · filed 2025-11-13 | $83.00K derived: sum of 2 quarters · filed 2025-11-13 | $126.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $40.00K 10-Q · filed 2025-08-14 | $83.00K 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |